Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Vertex Pharmaceuticals ( VRTX 2.72%) had a fine Tuesday on the stock exchange. The biotech 's shares closed the day nearly 3% ...

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

BNP Paribas Exane initiated coverage of Vertex (VERX) with an Outperform rating and $54 price target Stay Ahead of the Market: Discover ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. One of these two impactful publications was issued by Swiss bank UBS analyst Eliana Merle. The second of the pair ...

Vertex Pharmaceuticals is strutting toward its Q1 earnings report with a 22.3% stock surge this year, brushing up against its 52-week high. While analysts expect a dip in earnings per share, revenue ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy ... been insulin-independent for four years with normal-range HbA1c levels, according to a recent company ...

Vertex Pharmaceuticals got a healthy boost on Tuesday, with shares climbing nearly 3% thanks to a double dose of analyst ...

These mysterious droplets, known as biomolecular condensates, solidify when they carry a high proportion of the protein alpha-synuclein, the scientists reported in Science Advances. Clumps of ...